Related Experiment Video
Updated: Jul 9, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Pharmacotherapy for Parkinson's disease.
1Movement Disorders Center, Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, CA 92350, USA. jjchen@llu.edu
Pharmacotherapy
|November 29, 2007
Summary
Parkinson's disease pharmacotherapy focuses on symptom management, not neuroprotection. Early, well-tolerated treatment, like rasagiline (MAO-B inhibitor), may improve long-term outcomes in Parkinson's patients.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson's disease (PD) pharmacotherapies manage symptoms, lacking neuroprotective agents.
- Treatment choice requires balancing short-term benefits with long-term consequences.
Purpose of the Study:
- To review current pharmacotherapeutic strategies for Parkinson's disease.
- To emphasize personalized treatment approaches considering patient-specific factors.
Main Methods:
- Review of existing literature on Parkinson's disease pharmacotherapy.
- Analysis of treatment initiation, progression, and management strategies.
Main Results:
- Early initiation of well-tolerated agents like rasagiline (a monoamine oxidase [MAO]-B inhibitor) may improve long-term outcomes.
- Treatment decisions should integrate patient factors: age, disability, expectations, and prior responses.
- Progressive nature of PD necessitates ongoing pharmacotherapy adjustments.
Conclusions:
- Personalized pharmacotherapy is crucial for managing Parkinson's disease symptoms effectively.
- Nondopaminergic agents or dopamine agonists are increasingly used for initial monotherapy.
- Levodopa, catechol-O-methyltransferase inhibitors, MAO-B inhibitors, and amantadine are options for advanced disease stages or specific complications. Surgery is considered for refractory cases.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...